Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2-breast Cancer”

614 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 614 results

Not applicableLooking for participantsNCT05890287
What this trial is testing

Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Who this might be right for
HR Positive HER2 Negative Advanced Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 60
Large-scale testing (Phase 3)Active Not RecruitingNCT06635447
What this trial is testing

Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

Who this might be right for
Breast Cancer
AstraZeneca 293
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07367178
What this trial is testing

Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer

Who this might be right for
Breast CancerAdvanced HR+/HER2- Breast CancerAdvanced Triple-Negative Breast Cancer
MedSIR 30
Large-scale testing (Phase 3)Ended earlyNCT03326674
What this trial is testing

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 685
Not applicableStudy completedNCT07223476
What this trial is testing

Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 1,926
Large-scale testing (Phase 3)Enrolling By InvitationNCT05645536
What this trial is testing

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Who this might be right for
Breast Cancer
Tolmar Inc. 250
Not applicableNot Yet RecruitingNCT07553234
What this trial is testing

Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment

Who this might be right for
Breast Cancer
University of Chicago 20
Not applicableStudy completedNCT05132101
What this trial is testing

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Who this might be right for
Metastatic Breast Cancer
Pfizer 2,758
Testing effectiveness (Phase 2)UnknownNCT05044988
What this trial is testing

HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

Who this might be right for
HR+/HER2- Advanced and/or Metastatic Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)Study completedNCT04300790
What this trial is testing

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

Who this might be right for
Breast Cancer
MedSIR 69
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07767474
What this trial is testing

Evaluate ATX-898 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Antares Therapeutics, Inc 343
Not applicableActive Not RecruitingNCT07710716
What this trial is testing

A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 3,000
Early research (Phase 1)UnknownNCT04856371
What this trial is testing

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Haihe Biopharma Co., Ltd. 228
Large-scale testing (Phase 3)Ended earlyNCT04752332
What this trial is testing

Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

Who this might be right for
Breast Neoplasms
Eli Lilly and Company 111
Large-scale testing (Phase 3)Study completedNCT02028507
What this trial is testing

Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors

Who this might be right for
Metastatic Breast Cancer
Spanish Breast Cancer Research Group 693
Testing effectiveness (Phase 2)Looking for participantsNCT07288359
What this trial is testing

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals 205
Early research (Phase 1)Study completedNCT04481113
What this trial is testing

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8+17 more
OHSU Knight Cancer Institute 8
Large-scale testing (Phase 3)Study completedNCT02511639
What this trial is testing

Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer Metastatic
Istituto Oncologico Veneto IRCCS 110
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Early research (Phase 1)Looking for participantsNCT05996107
What this trial is testing

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
University of Michigan Rogel Cancer Center 30
Next Page